Evidence map›Paper›PMID 28386752›Full record

ArticleHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2017

Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats.

Adepu Anusha, Dudhipala Narendar, Boini Krishna Murthy, Puchchakayala Goverdhan

Abstract read
PubMed Publisher
In one paragraph

Article in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Development andNanotheranostics · 2023
    Article
  2. Pharmacokinetic Herb-Drug Interactions of Glipizide withMolecules (Basel, Switzerland) · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Adepu AnushaLaboratory of Pharmacokinetics and Toxicokinetics, Department of Pharmacology, Vaagdevi College of Pharmacy, Kakatiya University, Warangal, Telangana, 506001, India.
Dudhipala NarendarDepartment of Pharmaceutics, Vaagdevi Institute of Pharmaceutical Sciences, Warangal, Telangana, 506005, India.
Boini Krishna MurthyDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, 3455, Houston, TX, 77204, USA.
Puchchakayala GoverdhanLaboratory of Pharmacokinetics and Toxicokinetics, Department of Pharmacology, Vaagdevi College of Pharmacy, Kakatiya University, Warangal, Telangana, 506001, India. gov_ku@yahoo.co.in.
Kakatiya University · INUniversity of Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe present study was carried out to investigate the pharmacokinetic and pharmacodynamic drug interaction of irbesartan with glipizide after single and multi dose treatment in normal and hypertensive rat models to evaluate the safety and effectiveness of the combination.

methodsThe study was conducted on normal and 10% fructose solution induced hypertensive rats. Irbesartan and glipizide were administered orally for 7 days and on 8th day blood samples were collected for 12 h at regular time intervals from irbesartan alone and in combination with glipizide treated groups. The blood samples were analyzed for various pharmacokinetic and pharmacodynamic parameters.

resultsIrbesartan caused marked reduction in blood pressure in hypertensive rats. The combination of irbesartan and glipizide in hypertensive rats produce significant change in blood pressure (pharmacodynamic) and also significance in pharmacokinetic parameters of irbesartan with glipizide in single dose and multiple doses.

conclusionThe results of present study demonstrated that the synergistic activity of irbesartan with glipizide was observed.

Indexed as

Administration, OralAngiotensin II Type 1 Receptor BlockersAnimalsAntihypertensive AgentsBiological AvailabilityBiphenyl CompoundsBlood PressureCytochrome P-450 Enzyme SystemDisease Models, AnimalDrug Administration ScheduleDrug InteractionsFructoseGlipizideHypertensionHypoglycemic AgentsIrbesartanAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsBiphenyl CompoundsCYP2C9 protein, ratCytochrome P-450 Enzyme SystemFructoseGlipizideHypoglycemic AgentsIrbesartanTetrazolesAntihypertensive activityGlipizideIrbesartanPharmacodynamicPharmacokinetic

Identifiers

PMID28386752
OpenAlexW2605198363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.